-

Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026.

Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day.

About Edwards Lifesciences

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

Contacts

Media Contact: Amy Meshulam, media@edwards.com
Investor Contact: Mark Wilterding, investor_relations@edwards.com

Industry:

Edwards Lifesciences Corporation

NYSE:EW
Release Versions
English

Contacts

Media Contact: Amy Meshulam, media@edwards.com
Investor Contact: Mark Wilterding, investor_relations@edwards.com

More News From Edwards Lifesciences Corporation

Edwards Lifesciences Reports Third Quarter Results

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. Q3 Financial Highlights Q3 sales grew 10.5% to $1.72 billion1, constant currency2 sales grew 11.2% Q3 TAVR sales grew 8.0% to $1.24 billion1, constant currency2 sales grew 8.8% Q3 TMTT sales grew 44.0% to $207 million1,3, constant currency2 sales grew 45.6%3 Q3 EPS of $0.531; adjusted2 EPS of $0.801 which grew 19% versus prior year 2026 Outlook Increasing t...

CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System

SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR trial. The evidence further showed significant reduction of tricuspid regurgitation (TR) and substantially improved health status, both sustained through one year. The data were presented during late-breaking clinical trial sessions at Transcatheter Cardi...

Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features

SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demonstrated that transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in the primary composite endpoint of death or heart failure events at two years in moderate AS patients with at-risk features. The late-breaking results were presented at Transcatheter Cardiovascular Th...
Back to Newsroom